Have a feature idea you'd love to see implemented?
Let us know!
NGNE Neurogene Inc
Price (delayed)
$17.89
Market cap
$265.75M
P/E Ratio
0.56
Dividend/share
N/A
EPS
$31.92
Enterprise value
$211.9M
neoleukin therapeutics, inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. the company's lead product candidate is nl-201, a de novo protein designed
Highlights
NGNE's EPS has soared by 115% YoY
NGNE's equity has soared by 83% YoY but it is down by 11% QoQ
NGNE's debt is up by 23% year-on-year but it is down by 4.8% since the previous quarter
Neurogene's net income has decreased by 43% YoY and by 9% QoQ
NGNE's quick ratio is down by 41% YoY and by 25% from the previous quarter
Key stats
What are the main financial stats of NGNE
Market
Valuations
Earnings
Shares outstanding
14.85M
Market cap
$265.75M
Enterprise value
$211.9M
Price to book (P/B)
1.69
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Net income
-$71.13M
EBIT
-$71.11M
EBITDA
-$65.52M
Free cash flow
-$85.76M
Per share
Balance sheet
Liquidity
EPS
$31.92
EPS diluted
$7.09
Free cash flow per share
-$5.06
Book value per share
$10.58
Revenue per share
$0
TBVPS
$9.68
Total assets
$164.12M
Total liabilities
$26.71M
Debt
$13.12M
Equity
$137.41M
Working capital
$127.85M
Debt to equity
0.1
Current ratio
9.09
Quick ratio
8.82
Net debt/EBITDA
0.82
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-37.3%
Return on equity
-43.8%
Return on invested capital
-102.2%
Return on capital employed
-47.9%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
NGNE stock price
How has the Neurogene stock price performed over time
Intraday
-4.89%
1 week
-18.16%
1 month
-23.9%
1 year
-40.58%
YTD
-21.74%
QTD
-21.74%
Financial performance
How have Neurogene's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$93.83M
Net income
-$71.13M
Gross margin
N/A
Net margin
N/A
NGNE's operating income has dropped by 79% year-on-year and by 8% since the previous quarter
Neurogene's net income has decreased by 43% YoY and by 9% QoQ
Growth
What is Neurogene's growth rate over time
Valuation
What is Neurogene stock price valuation
P/E
0.56
P/B
1.69
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
NGNE's EPS has soared by 115% YoY
NGNE's equity has soared by 83% YoY but it is down by 11% QoQ
The stock's price to book (P/B) is 40% less than its last 4 quarters average of 2.8 and 16% less than its 5-year quarterly average of 2.0
Efficiency
How efficient is Neurogene business performance
The ROE has soared by 80% YoY
NGNE's return on assets is up by 27% year-on-year and by 2.1% since the previous quarter
The company's return on invested capital fell by 19% YoY
Dividends
What is NGNE's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for NGNE.
Financial health
How did Neurogene financials performed over time
Neurogene's total liabilities has soared by 86% YoY and by 8% from the previous quarter
The total assets has soared by 83% YoY but it has contracted by 9% from the previous quarter
NGNE's debt is 90% smaller than its equity
NGNE's equity has soared by 83% YoY but it is down by 11% QoQ
Neurogene's debt to equity has decreased by 29% YoY but it has increased by 11% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.